Close
provider
Search result for "Solr search content"
Search Result for "*:*"
provider
Neil Newman, MD Radiation Oncology, Thoracic Radiation Oncology
provider
Supreet Kaur, M.D. Hematology Oncology
provider
Colin Court, MD, PhD Surgical Oncology, Gastrointestinal Oncology
provider
Marcela Mazo Canola, MD Breast Oncology, Medical Oncology
provider
Shraddha Dalwadi, MD Radiation Oncology
provider
Federico Tozzi, MD Surgical Oncology, Surgery
Clinical Trial
A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE) (CTMS# 23-0101)
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP-binding site TKI with discontinuation due to treatment failure, warning, or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.